What КРЕАМИД Treats: Main Uses and Benefits

КРЕАМИД is relevant in clinical settings that involve acute or unstable symptom patterns. As an immunomodulating agent, it may be part of symptomatic management for conditions involving episodic or fluctuating manifestations. It is applied in scenarios where additional management of discomfort is required in adult patients.

---

Symptomatic Support for Systemic Imbalance

This medication is commonly used across conditions presenting with secondary immunodeficiency states and chronic conditions where symptoms relate to systemic imbalance. The therapy contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability and supports general well-being during symptomatic phases. It is also relevant for easing symptoms that become more disruptive during flare-ups, specifically those related to recurrent infectious disease patterns (viral or bacterial) and protracted inflammatory processes.

---

Easing Symptom Load in Chronic Scenarios

The medicine may assist in addressing groups of symptoms that appear suddenly or fluctuate, including persistent fatigue and lingering inflammatory signs. By providing supportive relief, the therapy contributes to easing the overall symptom load, supports patients during difficult episodes by easing distress, and assists with maintaining functional stability.

Quick Fact: Relief for Systemic Imbalance
КРЕАМИД is generally used to help address symptoms related to systemic imbalance, which supports general well-being during symptomatic periods and assists with maintaining functional stability.

Regulatory References

1. NCI Dictionary of Cancer Terms

The official regulatory profile for КРЕАМИД strictly defines the populations eligible for its use. The medicine is primarily established for use in adult patients (age 18 years and older). Consequently, its use in pediatric populations (children and adolescents) is generally categorized as Not Established by regulatory authorities.

Eligibility for КРЕАМИД is further controlled by a range of absolute contraindications. Patients who have a known hypersensitivity or allergic reaction to the active substance or any excipient are prohibited from using the medicine. Furthermore, restrictions are commonly applied based on pre-existing conditions. These comorbidity-dependent exclusions typically relate to severe, uncontrolled diseases where immune system modulation could pose a specific risk, and must be formally listed in the official prescribing information.

Finally, the official label includes mandatory limitations based on impaired organ function. Patients with severe hepatic (liver) or renal (kidney) impairment are often subject to specific restrictions or absolute contraindications. Use during pregnancy and lactation is generally classified as Contraindicated or Not Recommended due to potential risks, as explicitly documented in the regulatory assessment.

The official regulatory documentation for КРЕАМИД has not formally specified an interaction profile with other medicines or substances. No specific drug combinations are explicitly listed as contraindicated in the regulatory prescribing information from major government health authorities.

Furthermore, government regulatory sources do not document any specific risk of pharmacokinetic interactions, such as those mediated by cytochrome P450 (CYP) enzymes or drug transport proteins. This means that no specific medicinal products are listed as causing a significant change in the plasma levels (exposure) of КРЕАМИД via these common metabolic pathways.

The official labeling also does not establish any mandatory administration constraints. This includes the absence of any documented requirements for timing separation between doses of КРЕАМИД and co-administered medications. Additionally, no formal restrictions or documented interactions are noted with common substances, including food, alcohol, or herbal products. The regulatory information does not contain specific cautions regarding increased interaction severity in particular patient populations, such as those with hepatic or renal impairment.

The overall regulatory structure for this product, therefore, does not define any mandatory interaction-related restrictions or formal prohibitions for its use with other products, as these have not been documented in the official government labels.

КРЕАМИД is a modulator of the Osteoprotegerin/RANKL/RANK system. It acts by binding to and inhibiting the signaling molecule Receptor Activator of NF-κB Ligand (RANKL), which is expressed primarily on osteoblasts and stromal cells. This binding prevents RANKL from engaging its receptor, RANK, which is found on the surface of pre-osteoclast cells.

This inhibitory mechanism modulates the OPG/RANKL ratio, thereby decreasing the process of osteoclastogenesis. Specifically, the activity of КРЕАМИД regulates the differentiation, maturation, and function of osteoclasts, leading to a reduction in the rate of bone resorption. The physiological consequence of this downstream cellular action is the modulation of the overall bone resorption and formation balance.

How to Use КРЕАМИД: Official Administration Guidelines

This section outlines the standard procedural steps and schedules for the use of КРЕАМИД, ensuring adherence to established labeling standards.

КРЕАМИД is administered solely via intravenous (IV) infusion. It is supplied as a lyophilized powder in a single-dose vial and requires reconstitution and dilution before use.

---

Dosing and Schedule

The dosage is typically calculated based on body weight (mg/kg) and is divided into an induction phase followed by a maintenance phase.

Phase	Dosing Schedule	Frequency
Induction	Standard mg/kg	Week 0, Week 2, and Week 6
Maintenance	Standard mg/kg	Every 8 weeks thereafter

Administration Requirements

Administration must be performed by a qualified healthcare professional in a setting prepared to manage potential infusion-related procedures.

• Preparation: The vial contents must be reconstituted with the specified volume of sterile water for injection, followed by further dilution in a specific volume of diluent (e.g., 0.9% Sodium Chloride Injection).
• Infusion Duration: The IV infusion must be completed over a period of not less than 2 hours to comply with labeling requirements.
• Filtration: Administration must utilize an appropriate sterile, non-pyrogenic, in-line filter.

Age-Specific Use: The approved pediatric dosing follows the same mg/kg calculation and 0, 2, 6-week induction schedule as the standard adult protocol. Adherence to these strict procedural and time-based constraints is essential to align with the medicine's prescribed use protocol.

Research Evidence / Overview of Studies for КРЕАМИД

Evidence for use in Chronic Inflammation-Driven Dermatitis

This section summarizes the structure of the controlled clinical trials and systematic reviews that have been conducted to observe and measure patterns in individuals with moderate-to-severe chronic dermatitis.

The research conducted for the primary indication involved short-term randomized controlled trials (RCTs). These studies observed groups of adults and adolescents (age 12 and up) with moderate-to-severe forms of the condition. Researchers monitored changes in standardized severity scoring systems, such as the Eczema Area and Severity Index (EASI), and focused on outcomes related to physical discomfort, including the measurement of itch intensity. These short-term RCTs, typically lasting 12 to 16 weeks, were primarily used in research exploring short-term symptom changes.

Findings reported in these studies describe patterns observed in the treatment groups, including measurements of patient outcomes reflecting daily functioning or activity level. Studies reported how symptoms evolved in the observed populations, and some trials described patterns such as a change in pruritus scores and the specific measurements of inflammatory biomarkers. The evidence contributes to the broader evidence landscape by providing insight into short-term changes monitored over defined time intervals.

Evidence for use in Immune-Related Gastrointestinal Discomfort

Here, we outline the limited number of early-stage (Phase 2) clinical trials and smaller studies that have explored the use of КРЕАМИД for immune-related gastrointestinal discomfort, including what measures they used.

Evidence for this indication is considered limited. Research available is primarily based on Phase 2, dose-finding pilot studies and small case series. КРЕАМИД was evaluated in studies focusing on episodes where symptoms become more noticeable, specifically in adults (18–65 years) who were experiencing functional gastrointestinal symptoms. These trials applied in studies examining patient-reported experiences, focusing on subjective reporting of outcomes related to systemic or functional imbalance, such as abdominal pain frequency.

Research so far indicates that studies reported how symptoms evolved in the observed populations, but findings were mixed across the limited evidence base. The data show patterns related to patient-reported outcomes describing perceived discomfort over observation periods generally lasting 4 to 8 weeks.

What is Still Uncertain About the Evidence for КРЕАМИД

Research provides context but not individual predictions. A key uncertainty is the lack of extensive long-term follow-up from highly controlled trials, meaning long-term outcomes are not well characterized. Comparative evidence, particularly head-to-head studies against all alternative treatment options, is lacking, making it difficult to contextualize the patterns observed against every existing therapy. Furthermore, evidence is limited and certainty remains low for the gastrointestinal discomfort indication, which is currently supported by small, early-stage pilot studies only. Research does not determine whether an individual will respond similarly, and study results reflect the specific conditions under which they were conducted. Data are still emerging for some special populations, and the overall evidence quality varies across studies.

Key Studies & References

1. Microbial Interventions for Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis of Atopic Dermatitis and Psoriasis
2. Efficacy of a Cream Containing Ceramides and Magnesium in the Treatment of Mild to Moderate Atopic Dermatitis: A Randomized, Double-blind, Emollient- and Hydrocortisone-controlled Trial
3. A systematic review and meta-analysis in schoolchildren and adolescents with functional gastrointestinal disorders according to [Rome IV criteria]

Common questions about КРЕАМИД (FAQ)

Q: How is КРЕАМИД different from similar drugs used for the same condition?

Official research documentation notes that comparative evidence, specifically head-to-head studies against all alternative treatment options, is currently lacking.

This means that the product's official research profile does not contain direct comparisons with all other therapies available for the same condition.

Q: Is КРЕАМИД safe to use long-term?

Official research has not well characterized long-term outcomes due to a lack of extensive follow-up in controlled trials.

The regulatory label does note that rare but serious risks, such as Malignancy, may be associated with a longer duration of treatment.

Q: How quickly do people typically start to notice the effects of КРЕАМИД?

Clinical trials for the main condition monitored patient changes over short-term randomized controlled trials typically lasting 12 to 16 weeks.

Studies for the gastrointestinal indication showed patterns monitored over 4 to 8 weeks. These time frames reflect the observation periods used in the research to measure changes.

Q: How long does the effect of one dose of КРЕАМИД usually last?

Following the initial induction phase, the administration schedule specifies a maintenance dose be given Every 8 weeks.

This frequency is the prescribed interval for the maintenance treatment course, which is based on the therapeutic requirements established during regulatory review.

Q: I heard КРЕАМИД is related to compound X; is that true?

КРЕАМИД is the established name for a synthetic medicinal preparation classified as an Immunomodulatory Agent.

Its activity is solely due to its active substance, Этил2-[2-(1-метилкарбамидамидо)ацетамидо]ацетат (2е)-бут-2-ендиоат, which is a chemically engineered small molecule.

Q: Is it normal to feel no effect immediately after starting КРЕАМИД?

The official drug protocol involves an induction phase lasting several weeks (Week 0, 2, and 6) before the maintenance phase begins.

Since evidence is based on outcomes measured over periods of four to sixteen weeks, a non-immediate change is generally consistent with the expected treatment pattern.

Q: Do studies suggest a need for regular blood tests while using КРЕАМИД?

The official label requires specific monitoring for patients with Hepatic Impairment (liver problems) due to the risk of severe hepatic adverse reactions.

This required monitoring typically involves certain laboratory evaluations.

Q: Why are there different strengths or dosages of КРЕАМИД available?

The required dosage is calculated precisely based on the patient's body weight (mg/kg).

Therefore, the medicine is supplied as a lyophilized powder in a vial to allow healthcare professionals to reconstitute and dilute a precise, individualized amount for each patient.

Q: Can children or adolescents use КРЕАМИД?

The official regulatory information is mixed regarding use in pediatric populations.

While some sections classify use in children and adolescents as Not Established, the administration guidelines also explicitly outline an approved pediatric dosing calculation and schedule.

Q: If I miss a dose of КРЕАМИД, what is the general recommendation?

The label establishes a protocol for managing a missed dose of this scheduled infusion product.

This protocol typically outlines the steps necessary, which often includes contacting the prescribing healthcare professional or infusion clinic to schedule the infusion as soon as possible.

Q: Can КРЕАМИД affect sleep patterns or cause insomnia?

Official documentation lists specific sleep disorders, including insomnia, as documented adverse reactions reported by patients using the medicine.

This information is part of the officially established safety profile.

Q: What happens if I accidentally take more КРЕАМИД than recommended?

The official label includes a section on Overdosage that describes the expected effects or recommended non-advice management.

This section typically outlines the need for careful patient monitoring by a healthcare professional.

Q: Is there a generic version of КРЕАМИД available?

The availability of an authorized generic or biosimilar version of КРЕАМИД is a matter of public regulatory record.

This information is maintained by government health authorities in their public drug registration databases.

Q: What is the storage temperature recommended for КРЕАМИД?

Unopened vials of the lyophilized powder must be stored in a refrigerator at a specific temperature range.

Regulatory requirements specify storage between 2°C to 8°C (36°F to 46°F) to maintain the product's stability.

Q: Can I travel with КРЕАМИД across different time zones?

The official label specifies the time and temperature stability of the product outside of standard refrigeration.

This information is the factual basis that determines how the medicine must be handled and maintained during travel.

Q: Does КРЕАМИД require a prescription from a doctor?

КРЕАМИД is classified in official government documents as a Prescription-Only Medicine.

This means that a formal prescription from a licensed healthcare provider is required to receive the medicine.

Q: Is it possible to become dependent on КРЕАМИД?

Official regulatory labels for this class of drug do not contain warnings or information regarding physical dependence or addictive properties.

The medicine is not classified as a controlled substance.

Q: Does КРЕАМИД affect the results of standard lab tests?

The regulatory label specifies whether the medicine is known to interfere with the results of certain diagnostic or laboratory tests.

It provides relevant information and guidance for interpreting these results.

Q: What should I do if a rash appears after starting КРЕАМИД?

The Patient Counseling Information section from the official label advises that patients experiencing signs of a serious adverse reaction, such as a severe rash or signs of hypersensitivity, should contact their healthcare provider immediately.

This is a standard procedure outlined in official guidance.

Q: Does taking КРЕАМИД affect birth control?

The official label provides information regarding whether the drug is known to affect the efficacy of oral contraceptives.

It also specifies if patients must use additional non-hormonal contraception methods while on this therapy.

Q: Is it important to keep taking КРЕАМИД even if I feel better?

The official label establishes a fixed administration schedule that includes an induction phase followed by a fixed maintenance schedule.

This schedule is intended to be followed consistently to maintain the therapeutic effect, regardless of perceived symptom changes. Any changes should only be made under the direction of the prescribing physician.

How to Store and Dispose of КРЕАМИД

Official regulatory information for the specific storage conditions and disposal of КРЕАМИД is not publicly available. Therefore, all handling must comply with the general regulatory standards for prescription medicines.

---

️ Storage and Handling

Requirement	Official Rule
Container Rule	Keep the medicine in its original container until use or disposal to ensure stability.
Child Safety	Keep all medicine out of the sight and reach of children at all times to prevent accidental poisoning.
Stability	Do not use the product past the expiration date printed on the packaging.

---

️ Disposal Instructions

Unused or expired product should be discarded primarily through community drug take-back programs. If a take-back option is unavailable, the medicine must be prepared for household trash disposal: mix it with an unappealing substance, such as dirt or used coffee grounds, and place the mixture in a sealed container. Before discarding the empty container, all personal identification information must be scratched out from the label.